Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues.

Current drug targets - 1 Jan 2017

Feld Jordan J

Abstract excerpt

Treatment for hepatitis C virus (HCV) infection has progressed at remarkable speed. From poorly tolerated injectable therapy with very low cure rates, treatment has moved to highly effective well-tolerated all oral direct-acting antiviral therapies with cure rates above 90% for almost all patients populations. Direct-acting antivirals have developed out of an improved understanding of the viral lifecycle with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Clinical Trials as Topic
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Nucleic Acid Synthesis Inhibitors

Share to Protease Inhibitors

Share to Ribavirin

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 26302808
DOI: 10.2174/1389450116666150825111314

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues.PMID 26302808Read ↗

Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Semantic proximity Read ↗

Direct-acting antivirals: the endgame for hepatitis C?Semantic proximity Read ↗

Current therapy for chronic hepatitis C: The role of direct-acting antivirals.Semantic proximity Read ↗

Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.Semantic proximity Read ↗

Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.Semantic proximity Read ↗

What does the pharmacological future of treating chronic hepatitis C look like?Semantic proximity Read ↗

Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.Semantic proximity Read ↗

Update on the treatment of hepatitis C genotypes 2-6.Semantic proximity Read ↗

Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now.Semantic proximity Read ↗

[Treatment of chronic viral hepatitis C with direct acting antiviral agent: review].Semantic proximity Read ↗

The hepatitis C revolution part 1: antiviral treatment options.Semantic proximity Read ↗

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.